HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 22, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease, diabetes and other therapeutic areas, today announced that
HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 12, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that results from Part B of the Company’s STEADFAST Study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet co-primary efficacy endpoints.
HIGH POINT, N.C. --(BUSINESS WIRE)--May 31, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into an exclusive licensing agreement with Newsoara Biopharma Co., Ltd. for rights to develop and commercialize vTv Therapeutics’ PDE4 Inhibitor program
HIGH POINT, N.C. --(BUSINESS WIRE)--May 15, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial and operational results for the first quarter that ended March 31, 2018 . “We continue to make progress on all of our major programs,” said Steve Holcombe , chief executive officer, vTv
Subgroup of Mild Alzheimer’s Patients in Part A of Phase 3 STEADFAST Study Demonstrated Positive Benefit HIGH POINT, N.C. --(BUSINESS WIRE)--May 9, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that based on post-hoc analyses of the data from Part A of the Company’s Phase 3 STEADFAST
HIGH POINT, N.C. --(BUSINESS WIRE)--Apr. 9, 2018-- vTv Therapeutics, Inc. (vTv) (Nasdaq:VTVT) today announced that results from Part A of the Company’s Phase 3 STEADFAST study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet either co-primary
Simplici-T1 is an adaptive Phase 1b/2 study being conducted with support from JDRF HIGH POINT, N.C. --(BUSINESS WIRE)--Mar. 22, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the completion of Phase 1b of Simplici-T1, an adaptive Phase 1b/2 study assessing the pharmacokinetics,
HIGH POINT, N.C. --(BUSINESS WIRE)--Feb. 27, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today provided a corporate update and reported financial and operational results for the fourth quarter and full year that ended December 31, 2017 . “We made tremendous progress across the spectrum of our
HIGH POINT, N.C. --(BUSINESS WIRE)--Dec. 21, 2017-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into a global licensing agreement with Reneo Pharmaceuticals , a privately-held biotechnology company focused on developing treatments for orphan diseases.
HIGH POINT, N.C. --(BUSINESS WIRE)--Dec. 21, 2017-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into a licensing agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong Pharmaceutical”) , a wholly-owned subsidiary of Huadong Medicine